

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/670,724 25944 OU JEE & BER	09/26/2003 7590 01/08/200 RIDGE, PLC	Kelvin G.M. Brockbank	EXAMINER SAUCIER, SANDRA E	
OLIFF & BERRIDGE, PLC P.O. BOX 19928 ALEXANDRIA, VA 22320			ART UNIT . 1651	PAPER NUMBER
			MAIL DATE 01/08/2007	DELIVERY MODE

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/670,724	BROCKBANK ET AL.		
Examiner	Art Unit		
Sandra Saucier	1651		

	Sandra Saucier	1651					
The MAILING DATE of this communication appe	ears on the cover sheet with the d	orrespondence add	ress				
THE REPLY FILED 14 December 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods:	wing replies: (1) an amendment, affortice of Appeal (with appeal fee) in one with 37 CFR 1.114. The reply more	idavit, or other evider compliance with 37 C	rce, which FR 41.31; or (3)				
a) \square The period for reply expires 4 months from the mailing date	e of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date	• •	36(a) and the appropria	te extension fee				
have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropri inally set in the final Offi	ate extension fee ce action; or (2) as				
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	ns of the date of e appeal. Since				
a Notice of Appeal has been filed, any reply must be filed	I within the time period set forth in 3	37 CFR 41.37(a).					
AMENDMENTS	but when to the date of filling a brief	will not be entered by					
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE below)	nsideration and/or search (see NO		ecause				
(c) They are not deemed to place the application in be appeal; and/or	• •	ducing or simplifying	the issues for				
(d) They present additional claims without canceling a		ected claims.					
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1							
 The amendments are not in compliance with 37 CFR 1.1 Applicant's reply has overcome the following rejection(s) 		mpliant Amendment ((PTOL-324).				
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).							
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:		l be entered and an e	explanation of				
Claim(s) allowed:							
Claim(s) objected to: Claim(s) rejected:							
Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE							
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 							
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar 	overcome all rejections under appea	al and/or appellant fai	ls to provide a				
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	•		•				
 The request for reconsideration has been considered bu See Continuation Sheet. 	at does NOT place the application in	condition for allowar	nce because:				
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Paper No(s).	$\mathcal{L}(\mathcal{Q})$					
13. Other:		Software of the second	4				
		Sandra Saucier Primary Examiner					

Art Unit: 1651

Continuation of 3. NOTE: Insertion of the new limitations, never present in the prior claims "mammalian" and "0.2M" requires further consideration. Please note that the MPEP 714.13 states that the after final amendment should require only a cursory review. Insertion of new limitations is not considered to be "cursory".

Continuation of 11. does NOT place the application in condition for allowance because: While insertion of the limitation "mammalian" in the claims would overcome Kim and Burger, Crowe is still considered to be applicable prior art. Applicants urge that Crowe teaches against the increase of trehalose in the incubation medium over 90mM; however, this is not the general teaching of Crowe, but merely a specific teaching concerning platelet loading. The generic teaching of Crowe on page 5, is that the internal concentration of trehalose should be about 10-50mM in a non lyophilized erythrotic cell, PREFERABLY using a concentration of oligosaccharide up to about 50mM. In the case of platelets, concentrations in the incubation medium above about 50mM are not preferred (col. 13, I. 2). In another location the disclosure states, preferred concentrations of trehalose for platelet loading are less than 100mM because this retains normal morphology (col. 19, I. 15). However, these are merely preferable concentrations. A preference is different from a "teaching away" as applicants urge. In the absence of a direct comparison, the prior art of Crowe is considered to be still applicable to the newly submitted, but unentered claims.